# ELDN catalysts: Eledon Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eldn/catalysts

> Eledon Pharmaceuticals, Inc. (ELDN) has 4 upcoming catalysts. The next is the tegoprubart primary completion, March 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Eledon Pharmaceuticals, Inc. |
| Ticker | ELDN (Nasdaq) |
| SEC CIK | 1404281 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eldn |

## Cash runway

Cash $69.7M as of 2026-09-30; quarterly burn $19.0M; about 11.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-458564).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN |  | completed, positive | "In May 2022, we completed the Phase 2a study and released positive topline results." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1404281/000119312525283275/eldn-20250930.htm)) |
| November 12, 2024 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/eldn-ex99_1.htm)) |
| March 20, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-ex99_1.htm)) |
| May 14, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-ex99_1.htm)) |
| August 11, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-ex99_1.htm)) |
| September 11, 2025 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | completed | "NCT05983770 (Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05983770)) |
| Nov 2025 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN |  | scheduled | "We expect the last patient to be dosed in September 2025 and anticipate presenting topline results from the BESTOW study in November 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1404281/000119312525180906/eldn-20250630.htm)) |
| November 14, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/eldn-ex99_1.htm)) |
| March 19, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/eldn-ex99_1.htm)) |
| May 13, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-ex99_1.htm)) |
| August 13, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-ex99_1.htm)) |
| late 2026 | [Tegoprubart trial start](https://sec-api.dev/pdufa/tegoprubart) | ELDN |  | scheduled | ""We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526458378/eldn-ex99_1.htm)) |
| November 12, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526458378/eldn-ex99_1.htm)) |
| March 2029 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07835581)) |
| Mar to Jun 2029 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07835581)) |
| December 2029 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126380)) |
| Dec 2029 to Mar 2030 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126380)) |

## Drugs

- [Tegoprubart](https://sec-api.dev/pdufa/tegoprubart): Kidney Transplant Rejection

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eldn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ELDN catalysts: Eledon Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eldn/catalysts

```bibtex
@misc{secapidev_companies_eldn_catalysts_20261116,
  title        = {ELDN catalysts: Eledon Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eldn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eldn_catalysts_20261116","title":"ELDN catalysts: Eledon Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eldn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
